Ulimorelin
As of the edition of 20 October 2026, Ulimorelin is a small molecule: went quiet in 2018; acts on GHSR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 10, 0 stopped early
- Disease areas
- Digestive system; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Ulimorelin.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GHSR | Growth hormone secretagogue receptor type 1 | Q92847 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tranzyme | Lead sponsor of trials | 2006 to now |
| Norgine | Lead sponsor of trials | 2011 to now |
| Lyric Pharmaceuticals | Lead sponsor of trials | 2015 to now |